Randomised, Double-Blind, Placebo-Controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ivabradine (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms Riviera
- 07 Jun 2017 Biomarkers information updated
- 05 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Apr 2011 Lead trial investigator (Alberto Dominguez Rodriguez) added as reported by ClinicalTrials.gov.